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Introduction
In developing and adult mammalian skeletal muscle, the TGF- 
signaling network functions as a dominant repressor of protein 
anabolism and a principal driver of protein catabolism underly-
ing muscle wasting. These effects have been attributed to TGF- 
family members (most notably myostatin and activin) that en-
gage activin receptors and stimulate the Smad2/3 signaling pro-
teins to mediate the transcriptional activity of genes controlling 
cell size. Inhibition of the myostatin/activin–Smad2/3 axis has 
been proposed as a potential therapeutic strategy for treating 
conditions associated with loss of muscle mass and strength as 
(a) deletion of myostatin (Kambadur et al., 1997; McPherron 
et al., 1997; Lee and McPherron, 2001; Lee, 2007); (b) antagonism 
of myostatin by inhibitory proteins, antibodies, or soluble activin 
receptors (Bogdanovich et al., 2002; Zhou et al., 2010; Winbanks 
et al., 2012); or (c) inhibition of Smad2/3 (Sartori et al., 2009; 
Winbanks et al., 2012) can promote muscle growth and amelio-
rate muscle wasting. Within the TGF- network, the parallel 
signaling axis controlled by bone morphogenetic proteins (BMPs) 
regulates the transcription of target genes distinct to those regu-
lated by the myostatin/activin–Smad2/3 axis (Massagué et al., 
2005). Although some studies suggest that BMP signaling may 
regulate embryonic muscle development (Pourquié et al., 1996; 
Amthor et al., 1998) or the regeneration of skeletal muscle 
(Clever et al., 2010; Ruschke et al., 2012), research to date 
provides limited insight into whether or not BMP signaling 
operates in postmitotic myofibers to directly regulate the skeletal 
muscle phenotype.
BMP ligands engage specific membrane-bound serine/
threonine kinase receptors that convey signals to intracellu-
lar Smad proteins 1, 5, and 8. Phosphorylation of Smad1/5/8 
Although the canonical transforming growth factor  signaling pathway represses skeletal muscle growth and promotes muscle wasting, a role in 
muscle for the parallel bone morphogenetic protein (BMP) 
signaling pathway has not been defined. We report, for the 
first time, that the BMP pathway is a positive regulator of 
muscle mass. Increasing the expression of BMP7 or the ac-
tivity of BMP receptors in muscles induced hypertrophy that 
was dependent on Smad1/5-mediated activation of mTOR 
signaling. In agreement, we observed that BMP signal-
ing is augmented in models of muscle growth. Importantly, 
stimulation of BMP signaling is essential for conservation 
of muscle mass after disruption of the neuromuscular 
junction. Inhibiting the phosphorylation of Smad1/5 ex-
acerbated denervation-induced muscle atrophy via an 
HDAC4-myogenin–dependent process, whereas increased 
BMP–Smad1/5 activity protected muscles from denerva-
tion-induced wasting. Our studies highlight a novel role for 
the BMP signaling pathway in promoting muscle growth 
and inhibiting muscle wasting, which may have significant 
implications for the development of therapeutics for neuro-
muscular disorders.
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ALK3 increased the phosphorylation of pAktS473, mTORS2448, 
and the downstream targets S6RPS235/236 and 4EBP1T37/46 (Fig. 1 h). 
We did not observe altered abundance or phosphorylation of 
Foxo1/3, or expression of the muscle-specific E3 ligases MuRF1 
and Atrogin1 in response to rAAV6:BMP7 (Fig. S1, b and c), 
demonstrating that hypertrophy driven by enhancing BMP sig-
naling in healthy muscles is not a product of altering this key 
mechanism of muscle protein degradation. As the activity of 
mTOR is a key regulator of protein synthesis in muscle, we 
sought to determine whether muscle growth induced by BMP 
signaling was dependent on activation of mTOR. We established 
that rAAV6:BMP7-induced S6RPS235/236 phosphorylation was 
completely ablated by coadministration of rapamycin (Fig. 1 i), a 
specific inhibitor of mTORC1 signaling (Heitman et al., 1991; 
Chung et al., 1992). Rapamycin completely prevented rAAV6:
BMP7-induced increases in muscle mass and myofiber size 
(Fig. 1, j and k; and Fig. S1 d), despite continued overexpres-
sion of BMP7 (Fig. S1, e and f) and increased phosphorylation 
of Smad1/5 (Fig. S1 g). These data constitute the first demon-
stration that the BMP signaling axis is a bona fide regulator of 
skeletal muscle growth and that the mTORC1 pathway is indis-
pensable in this process.
BMP7-induced skeletal muscle hypertrophy 
is mediated by Smad1/5/8
To directly test the role of the BMP-regulated Smads (Smad1/5/8) 
in the regulation of muscle hypertrophy, we designed an rAAV6 
vector encoding Smad6 (rAAV6:Smad6), which inhibits phos-
phorylation of BMP-regulated Smads (Imamura et al., 1997; 
Ishida et al., 2000). In cultures of C2C12 cells, Smad6 potently 
blocked BMP4-induced activation of a BMP activity-sensing 
luciferase reporter (Fig. 2 a). Administration of rAAV6:Smad6 
in vivo potently suppressed the phosphorylation of Smad1/5S463/465 
in TA muscles, but did not alter the mass of muscles examined 
28 d after administration (Fig. 2 b and Fig. S2, a and b). To test 
the importance of the BMP-regulated Smads in controlling 
BMP7-induced hypertrophy, rAAV6:Smad6 was codelivered 
with rAAV6:BMP7 to the TA muscles of mice. At 28 d after ad-
ministration, Smad6 had completely prevented muscle hyper-
trophy (Fig. 2, b and c) and increases in myofiber size (Fig. 2 d) 
normally induced by rAAV6:BMP7. As predicted, Smad6 potently 
suppressed BMP7-induced phosphorylation of Smad1/5S463/465 
(Fig. 2 e). Importantly, we found that rAAV6:Smad6 also sup-
pressed BMP7-induced phosphorylation of AktS473, mTORS2448, 
S6RPS235/236, and 4EBP1T37/46 (Fig. 2 f). Administration of rAAV6:
Smad6 alone did not affect mTOR signaling (Fig. S2 c). These 
data demonstrate that the BMP signaling axis regulates skeletal 
muscle mass via the activation of Smads1/5/8 and that the sup-
pression of BMP-regulated Smads by Smad6 can inhibit mTOR 
activation downstream of Smad1/5, which is required for mus-
cle hypertrophy.
Endogenous BMP signaling is altered in 
models of muscle growth
To further explore the significance of the BMP axis as a regula-
tor of skeletal muscle growth, we analyzed Smad1/5S463/465 
phosphorylation in skeletal muscles undergoing hypertrophy. 
by BMP-stimulated receptors promotes complex formation with 
Smad4 and nuclear retention where, in cooperation with tran-
scriptional coregulators, they govern gene expression in a cell- 
and context-dependent manner (Massagué et al., 2005). BMP 
signaling is negatively regulated by Smad proteins 6 and 7, which 
prevent receptor-mediated activation of Smad1/5/8 (Hayashi 
et al., 1997; Imamura et al., 1997; Nakao et al., 1997). The com-
plexity of the TGF- signaling network includes cross-regulation 
between the myostatin/activin–Smad2/3 and BMP–Smad1/5/8 
axes. Ligands can compete for common serine/threonine ki-
nase receptors (Donaldson et al., 1992; Mathews et al., 1992; 
Rebbapragada et al., 2003; Sako et al., 2010) to promote forma-
tion of so-called mixed R-Smad complexes (e.g., Smad1/3/5) that 
can activate and perturb the transcription of respective TGF- 
and BMP target genes (Grönroos et al., 2012). Thus, the canoni-
cal TGF- and BMP signaling axes have the potential to operate 
in parallel and reciprocally.
Based on the pivotal role that the myostatin/activin–
Smad2/3 axis plays in regulating skeletal muscle mass and the 
hypothesized parallel operation of TGF- and BMP signaling, 
we sought to determine the role of the BMP–Smad1/5/8 signaling 
pathway in the regulation of skeletal muscle growth and wasting. 
In contrast to the established negative influence of the myostatin/
activin–Smad2/3 axis on muscle mass, herein we identify the 
BMP–Smad1/5/8 axis as a positive regulator of skeletal mus-
cle mass in vivo, promoting muscle growth and preventing 
muscle wasting. Interventions that stimulate the BMP–Smad1/5/8 
signaling axis may offer therapeutic benefits in preventing or 
ameliorating pathology associated with muscle wasting.
Results
BMP ligands and BMP receptor activation 
promotes skeletal muscle hypertrophy
To determine whether the BMP axis can regulate postnatal 
skeletal muscle growth, we designed rAAV6 vectors encoding 
BMP7 (rAAV6:BMP7) or a constitutively active type I BMP re-
ceptor (rAAV6:ALK3). rAAV6:BMP7 and rAAV6:ALK3 sig-
nificantly increased the activity of a BMP luciferase reporter 
construct transfected into C2C12 cells (Fig. 1 a). When deliv-
ered to mouse tibialis anterior (TA) hindlimb muscles, rAAV6:
BMP7 and rAAV6:ALK3 increased BMP7 and ALK3 protein 
and mRNA expression, respectively (Fig. 1 b), and increased 
Smad1/5S463/465 phosphorylation (Fig. 1 c). Significantly, admin-
istration of rAAV6:BMP7 and rAAV6:ALK3 to the TA muscles 
of 8-wk-old mice considerably increased skeletal muscle mass 
within 28 d of injection (Fig. 1 d). Histological examination re-
vealed that the increase in muscle mass after rAAV6:BMP7 or 
rAAV6:ALK3 administration was a product of muscle fiber hy-
pertrophy (Fig. 1 e), as demonstrated by increases in myofiber 
diameter and area (Fig. 1 f). We also determined that muscles 
injected with rAAV6:BMP7 or rAAV6:ALK3 demonstrated 
increased transcription of insulin-like growth factor (IGF) iso-
forms, which can promote striated muscle growth (Musarò 
et al., 1999; Kalista et al., 2012; Fig. 1 g and Fig. S1 a). As IGF 
proteins can potentiate PI3K/Akt/mTOR signaling (Rommel et al., 
2001), we also determined that rAAV6:BMP7 and rAAV6:
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that increased expression of Smad6 significantly suppressed 
the phosphorylation of Smad1/5 in response to follistatin 
overexpression (Fig. S3 f). Previously, we established that 
follistatin-mediated muscle hypertrophy promotes activation of 
the Akt/mTOR/S6RP/4EBP cascade to stimulate protein synthesis 
(Winbanks et al., 2012). Here, the suppression of follistatin-
mediated muscle hypertrophy by rAAV6:Smad6 suppressed 
the phosphorylation of AktS473, mTORS2448, S6RPS235/236, and 
4EBP1T37/46 (Fig. S3 g). These results demonstrate that hyper-
trophy of skeletal muscle can involve recruitment of the BMP 
signaling pathway.
We found that in skeletal muscles expressing follistatin (via 
rAAV6:Fst-288 injection), a protein that promotes hypertro-
phy by preventing myostatin and activin from engaging ac-
tivin receptors (Lee, 2007; Lee et al., 2010; Winbanks et al., 
2012), Smad1/5S463/465 phosphorylation was increased (Fig. S3 a). 
The increases in Smad1/5S463/465 phosphorylation were as-
sociated with decreased Smad6 expression in muscles under-
going follistatin-induced hypertrophy (Fig. S3 b). When we 
coadministered rAAV6:Smad6 with rAAV6:Fst-288 to the 
TA muscles of mice, follistatin-induced hypertrophy of mus-
cle fibers was profoundly blunted (Fig. S3, c–e). We confirmed 
Figure 1. Postnatal expression of BMP7 and 
ALK3 promotes skeletal muscle hypertrophy. 
(a) Plasmids expressing BMP7 or constitutively 
active type-IA BMP receptor (ALK3) were trans-
fected into C2C12 cells along with plasmids 
expressing a BMP luciferase reporter and 
-galactosidase 48 h before examination 
(*, P < 0.001 vs. control). Figure represents 
three independent experiments, with each in-
dividual experiment performed in triplicate. 
(b) The administration of rAAV6:BMP7 or 
rAAV6:ALK3 to mouse limb muscles resulted in 
significant increases in BMP7 (n = 4 per treat-
ment) and ALK3 (n = 4 per treatment) protein 
and gene expression, respectively, when ex-
amined 28 d after injection (*, P = 0.005 vs. 
control; #, P = 0.04 vs. control). (c) rAAV6:
BMP7 (n = 4 per treatment) and rAAV6:ALK3 
(n = 4 per treatment) significantly increased 
the phosphorylation of Smad1/5S463/465  
(*, P < 0.001 vs. control; #, P = 0.009 vs. control). 
(d) Injection of the anterior musculature of the 
mouse hindlimb with rAAV6:BMP7 (n = 11) or 
rAAV6:ALK3 (n = 4 per treatment) increased 
muscle mass by 25% (*, P < 0.001 vs. con-
trol). Bars, 5 mm. (e and f) Muscle hypertrophy 
was a product of increased muscle fiber size 
as demonstrated by representative H&E-stained 
cryosections and quantification of myofiber 
diameter (represented as box and whisker 
plots comprising minimum, lower quartile, me-
dian, upper quartile, and maximum values for 
myofiber diameter; *, P = 0.004 vs. control; 
#, P = 0.008 vs. control) and myofiber area 
(*, P = 0.045 vs. control; #, P = 0.01 vs. 
control; n = 3 per treatment). Bars, 100 µm. 
(g) IGF1 and IGF2 mRNA expression was deter-
mined 28 d after rAAV6:BMP7 administration 
(*, P = 0.03 vs. control; n = 7–9 per treat-
ment). (h) Muscles examined 28 d after injec-
tion of rAAV6:BMP7 (n = 5–8 per treatment) or 
rAAV6:ALK3 (n = 4–11 per treatment) demon-
strated significant increases in phosphorylation 
of AktS473 (*, P = 0.03 vs. control; #, P = 0.008 
vs. control), mTORS2448 (*, P = 0.04 vs. con-
trol; #, P = 0.01 vs. control), S6RPS235/236  
(*, P = 0.04 vs. control; #, P = 0.03 vs. control), 
and 4EBP1T37/46 (*, P = 0.004 vs. control; 
#, P = 0.02 vs. control). (i) When administered 
at 1 mg/kg/day, rapamycin attenuated BMP7-
induced phosphorylation of S6RPS235/236 when 
compared with muscles expressing BMP7 that 
were collected with animals receiving vehicle 
(*, P < 0.001 vs. control; n = 4–5 per treat-
ment). (j) Intraperitoneal injections of rapamycin for 28 d completely prevented the ability of BMP7 (n = 5–7 per treatment) to induce skeletal muscle growth. 
The muscle hypertrophy induced by BMP7 is presented as a percentage increase in the presence of either sham or rapamycin (*, P = 0.002 vs. control). 
(k) Increases in myofiber diameter and area typically observed in muscles examined 28 d after injection of rAAV6:BMP7 were prevented by coadministra-
tion of rapamycin (*, P = 0.003 vs. control; #, P < 0.001 vs. control; n = 3 per treatment). Data for myofiber diameter are presented as box and whisker 
plots comprising minimum, lower quartile, median, upper quartile, and maximum values. Data are presented as means ± SEM.
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mice modeling amyotrophic lateral sclerosis (via a mutation in 
the superoxide dismutase gene, designated SOD1G93A) at ages 
preceding marked loss of muscle mass (60 d) or coinciding 
with observable muscle atrophy (90 d; Gurney et al., 1994; 
Fig. 3 c). Confirming that Smad1/5 phosphorylation increases 
in muscles when motor nerve activity is compromised, we also 
detected striking increases in Smad1/5S463/465 phosphorylation 
in TA muscles from mice subjected to motor nerve resection 
(Fig. 3 d). Smad1/5 phosphorylation was increased in muscles as 
early as 3 d after denervation and remained increased for at least 
14 d after denervation (Fig. 3 d). To explore why Smad1/5S463/465 
phosphorylation was increased in response to loss of nerve sup-
ply to skeletal muscle, we profiled the expression of the BMP 
pathway components in denervated skeletal muscles. We identi-
fied profoundly increased transcription of the BMP receptor li-
gands GDF5 (BMP14) and GDF6 (BMP13) and the type-IB 
BMP receptor (ALK6; Fig. 3, e and f), but not other BMP li-
gands (Fig. S4 a) or the type-IA BMP receptor (ALK3; Fig. 3 f). 
We also found that transcription of Smad6 and Noggin, the latter 
Differential BMP–Smad1/5 signaling in 
muscle development and disease
As BMP signaling promotes hypertrophy of mature skeletal 
muscle fibers, we considered whether the activity of this path-
way contributes to muscle growth during postnatal maturation 
and becomes affected in muscle wasting conditions. Skeletal 
muscle protein synthesis in rodents is highest up to 1 wk after birth, 
before progressively declining to stable adult levels (Suryawan 
et al., 2006). We found that the phosphorylation of Smad1/5S463/465 
declined markedly from 1 wk after birth until 6 mo of age 
(Fig. 3 a), consistent with BMP signaling participating in the 
development of skeletal musculature. To determine the role 
of BMP signaling in skeletal muscle wasting, we examined 
Smad1/5 phosphorylation in muscles exhibiting wasting associ-
ated with motor nerve degeneration, transection, or blockade. In 
TA muscles from rats subjected to intensive care disuse for up 
to 9 d, Smad1/5S463/465 phosphorylation was increased coincident 
with a decrease in TA mass (Fig. 3 b). Similarly, Smad1/5S463/465 
phosphorylation was markedly increased in TA muscles from 
Figure 2. BMP7-induced skeletal muscle growth is mediated 
by Smad1/5. (a) rAAV6:Smad6 was applied to C2C12 cells 
to determine its ability to suppress BMP4-induced BRE-luciferase 
activity. After administration of vector, cells were treated for 
24 h with 3 nM BMP4 and then lysed to assess luciferase 
activity (*, P < 0.001 vs. control). Figure represents three 
independent experiments, with each individual experiment 
performed in triplicate. (b) The coadministration of rAAV6:
Smad6 with rAAV6:BMP7 significantly attenuated BMP7- 
induced hypertrophy in mouse limb muscles, as determined by 
changes in TA muscle mass (*, P < 0.001 vs. control). Muscles 
expressing both BMP7 and Smad6 did not differ compared 
with control muscles when examined 28 d after injection (ND, 
not different). n = 4–10 per treatment. (c) Image of TA muscles 
demonstrating BMP7-induced hypertrophy and the inhibitory 
effect of Smad6 coexpression. Bar, 5 mm. (d) Representa-
tive images and myofiber diameter and area quantification 
demonstrate that BMP7-induced myofiber hypertrophy is 
significantly suppressed by Smad6 (*, P = 0.01 vs. control; 
#, P = 0.02 vs. control; n = 3 per treatment). Myofiber diam-
eter is presented as box and whisker plots comprising mini-
mum, lower quartile, median, upper quartile, and maximum 
values for myofiber diameter. Muscles coexpressing BMP7 
and Smad6 were not different from control muscles 28 d after 
injection (ND, not different). Bar, 100 µm. (e) Smad6 coad-
ministration reduced the phosphorylation of Smad1/5S463/465 
normally induced 28 d after injection of rAAV6:BMP7 alone, 
as determined by Western blot analysis (*, P < 0.001 vs. con-
trol; #, P < 0.05 vs. control; +, P < 0.001 vs. BMP7-treated 
muscles; n = 5–10 per treatment). (f) Smad6 coadministra-
tion reduced the phosphorylation of AktS473 (*, P < 0.001 
vs. control; #, P = 0.003 vs. BMP7 treatment), mTORS2448 
(*, P = 0.006 vs. control; #, P = 0.005 vs. BMP7 treatment), 
S6RPS235/236 (*, P = 0.04 vs. control; #, P = 0.004 vs. BMP7 
treatment), and 4EBP1T37/46 (*, P = 0.009 vs. control; #, P = 
0.004 vs. BMP7 treatment) when compared with the effect of 
BMP7 alone. n = 4–8 per treatment. Data are presented as 
means ± SEM.
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atrophy of denervated muscles, compared with denervation alone 
(Fig. 4, a–c). Importantly, increased Smad6 expression potently 
suppressed Smad1/5 phosphorylation in denervated muscles 
(Fig. 4 d), confirming that inhibition of Smad1/5 phosphorylation 
is associated with the exacerbation of denervation-induced mus-
cle atrophy. Supporting this concept, we showed that pretreat-
ment of TA muscles with rAAV6:BMP7 28 d before denervation 
reduced muscle loss (Fig. 4 e) and decreases in myofiber size 
(Fig. 4, f and g). Administration of rAAV6:ALK3 also reduced 
denervation-induced muscle atrophy and preserved myofiber 
size (Fig. 4, h–j). These data demonstrate that augmented BMP–
Smad1/5 signaling performs a critical role in limiting muscle 
wasting associated with denervation.
The BMP signaling axis regulates  
the expression of E3 ligases via the 
HDAC4–myogenin axis associated with 
neurogenic atrophy
To gain insight into how the BMP signaling pathway may pre-
vent neurogenic muscle wasting, we examined denervated skel-
etal muscles treated with rAAV6:Smad6 for changes in the 
expression of E3 ubiquitin ligases. The ubiquitination of protein 
of which antagonizes extracellular BMP ligands (Holley et al., 
1996; Zimmerman et al., 1996), was suppressed at all time points 
examined after denervation where Smad1/5S463/465 phosphoryla-
tion was increased (Fig. 3 g). The transcription of other BMP axis 
repressors including Smad7, Smurf1/2, or Chordin was not 
altered (Fig. S4 b). These data identify that the expression of 
BMP axis elements is altered to promote Smad1/5S463/465 phos-
phorylation in muscles exhibiting wasting associated with motor 
nerve transaction, degeneration, or disuse.
BMP signaling protects skeletal muscle 
from denervation-induced atrophy
Having identified that phosphorylation of Smad1/5 is increased 
in muscles undergoing wasting associated with nerve transection, 
degeneration, and inactivity, we next sought to determine the 
functional role of increased Smad1/5S463/465 phosphorylation in 
the muscles’ response to denervation. Because Smad6 is an en-
dogenous inhibitor of Smad1/5 phosphorylation and we found 
that its expression decreased in denervation, we administered 
rAAV6:Smad6 to muscles at the time of motor nerve resection 
to prevent BMP–Smad1/5 signaling. Strikingly, we found that 
the administration of rAAV6:Smad6 considerably exacerbated 
Figure 3. Endogenous BMP signaling is al-
tered in models of skeletal muscle growth and 
wasting. (a) TA muscles were collected from 
neonatal and young adult mice and the phos-
phorylation of Smad1/5 was determined by 
Western blotting (*, P < 0.001 vs. control). 
n = 3 per time point. (b) Rats subjected to in-
tensive care immobilization (n = 3–6 per treat-
ment) displayed muscle atrophy with increased 
phosphorylation of pSmad1/5 (*, P = 0.01 
vs. control muscles; +, P = 0.002 vs. control 
muscles; #, P < 0.001 vs. control muscles). 
(c) Smad1/5S463/465 phosphorylation was as-
sessed in mice (n = 5 per treatment) with a 
SOD1G93A mutation that displays symptoms 
akin to amyotrophic lateral sclerosis patients. 
At a time point before the onset of muscle at-
rophy (60 d; *, P = 0.001 vs. control) and at 
a point of advanced pathology (90 d; #, P < 
0.001 vs. control) Smad1/5 phosphorylation 
was increased. (d) Smad1/5S463/465 phos-
phorylation was assessed by Western blot 3 d 
(n = 5 per treatment; *, P = 0.007 vs. con-
trol), 7 d (n = 6 per treatment; *, P = 0.002 
vs. control), and 14 d (n = 5–6 per treatment; 
*, P = 0.002 vs. control) after excision of a 
portion of the peroneal nerve supplying the 
TA muscle in wild-type mice. (e–g) mRNA ex-
pression of GDF6 (BMP13), GDF5 (BMP14), 
BMPR1A, BMPR1B, Smad6, and Noggin was 
assessed by RT-PCR (n = 4–6 per treatment; 
see specific time points for p-values). Gene ex-
pression was analyzed using the CT method 
of analysis and expression was normalized to 
18S. Data are presented as means ± SEM.
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of another E3 ubiquitin ligase, Fbxo30, in correlation with 
markers of motor nerve degeneration (Ibebunjo et al., 2013). 
Emerging evidence points to Fbxo30 (also referred to as Musa1) 
as a novel atrophy-associated E3 ligase in skeletal muscle (Sartori 
et al., 2013). We found transcription of Fbxo30/Musa1 was 
increased in denervated muscles at all time points examined 
after nerve resection (Fig. 5 a). Even more significantly, the ex-
pression of Fbxo30/Musa1 was markedly potentiated in dener-
vated muscles in association with exacerbated atrophy when 
targets (such as contractile proteins) by specific E3 ligases includ-
ing MuRF1 and atrogin1 plays a key role in proteasome-mediated 
protein degradation associated with muscle wasting (Bodine et al., 
2001; Cohen et al., 2009). We found that the transcription of 
MuRF1 and atrogin1 was increased in denervated muscles trans-
duced with rAAV6:Smad6, compared with denervated muscles 
receiving a sham vector (Fig. 5 a). Profiling of gene expression 
associated with sarcopenic wasting in old rats (where progres-
sive motor nerve loss occurs) recently documented up-regulation 
Figure 4. BMP signaling protects skeletal muscle from wast-
ing in denervation. (a) rAAV6:Smad6 was delivered to the 
TA muscles immediately after denervation. Muscle masses 
were then assessed 3 d (n = 6 per treatment), 7 d (n = 5–6 
per treatment; *, P = 0.002 vs. control; #, P = 0.04 vs. de-
nervation), and 14 d (n = 4–6 per treatment; *, P < 0.001 
vs. control; #, P < 0.001 vs. denervation) after denervation. 
(b) Smad6 gene expression increased at 3 d (n = 6 per treat-
ment; *, P = 0.05 vs. control), 7 d (n = 5 per treatment; *, P = 
0.04 vs. control), and 14 d (n = 6 per treatment; *, P < 0.001 
vs. control) after injection in denervated TA muscles. (c) De-
nervated TA muscles treated with rAAV6:Smad6 appeared 
smaller than denervated muscles 14 d after denervation. Bar, 
5 mm. (d) Expression of Smad6 in TA muscles denervated 
for 3 d (n = 5–10 per treatment; *, P < 0.05 vs. control; 
#, P = 0.001 vs. control; +, P < 0.001 vs. denervation) and 
7 d (n = 6–12 per treatment; *, P = 0.04 vs. control; #, P < 
0.001 vs. control; +, P = 0.002 vs. denervation) correlated 
with suppression of Smad1/5S463/465 phosphorylation, as de-
termined by Western blotting. (e) TA muscles were pretreated 
with rAAV6:BMP7 for 28 d and then denervated 14 d before 
tissue collection. Although denervation induced 30% loss 
of muscle mass, increased expression of BMP7 significantly 
diminished muscle atrophy (n = 3 sham and 6 den; *, P < 0.001 
vs. control; #, P < 0.001 vs. control; +, P = 0.02 vs. denerva-
tion). (f and g) Representative H&E images and quantifica-
tion of myofiber diameter and area demonstrates that loss of 
myofiber diameter (*, P < 0.001 vs. control; #, P < 0.001 vs. 
control; +, P < 0.001 vs. denervation) and area (*, P < 0.001 
vs. control; #, P < 0.001 vs. control; +, P < 0.001 vs. den, 
n = 3 per treatment) after denervation can be ameliorated by 
rAAV6:BMP7 administration. Myofiber diameter is presented 
as box and whisker plots comprising minimum, lower quar-
tile, median, upper quartile, and maximum values for myo-
fiber diameter. (h) TA muscles were pretreated with rAAV6:
ALK3 for 28 d and then denervated 14 d before sample col-
lection. rAAV6:ALK3 significantly reduced muscle atrophy 
(n = 3 sham and 4 den; *, P = 0.009 vs. control; #, P < 
0.001 vs. control; +, P = 0.01 vs. denervation). (i and j) 
Representative H&E images and quantification of myofiber di-
ameter and area demonstrates that loss of myofiber diameter 
(*, P < 0.001 vs. control; #, P < 0.001 vs. control; +, P = 
0.001 vs. denervation) and area (*, P < 0.001 vs. control; 
#, P < 0.001 vs. control; +, P = 0.004 vs. den; n = 3 per treat-
ment) after denervation can be diminished by rAAV6:ALK3 
administration. Myofiber diameter is presented as box and 
whisker plots comprising minimum, lower quartile, median, 
upper quartile, and maximum values for myofiber diameter. 
Bar, 100 µm. Data are presented as means ± SEM.
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2005). However, we found that rAAV6:Smad6 did not alter 
phosphorylation of FoxO1T24/FoxO3aT32 or affect AktS473 phos-
phorylation in denervated muscles (Fig. S4 c). As an alternate 
mechanism, we assessed the HDAC4–myogenin axis, as dele-
tion of either HDAC4 or myogenin renders skeletal muscles re-
sistant to neurogenic atrophy and prevents the up-regulation of 
MuRF1 and atrogin1 (Tang et al., 2009; Moresi et al., 2010). 
Strikingly, we found that inhibiting BMP–Smad1/5 signaling in 
BMP–Smad1/5 signaling was inhibited by administration of 
rAAV6:Smad6 (Fig. 5 a).
We sought to determine how changes in BMP–Smad1/5 
signaling regulate transcription of the aforementioned E3 ligases 
that contribute to proteolysis in muscles. Expression of MuRF1 
and atrogin1 is promoted by nuclear translocation of the FoxO 
proteins (Sandri et al., 2004), which, in turn, is repressed by Akt 
kinase activity (Sandri et al., 2004; Stitt et al., 2004; Latres et al., 
Figure 5. The BMP signaling axis regulates 
the expression of E3 ubiquitin ligases via the 
HDAC4–myogenin axis in neurogenic muscle 
wasting. (a) The E3 ligase atrogin1 was de-
tected by RT-PCR 3 d (n = 3–6 per treatment; 
*, P < 0.05 vs. control), 7 d (n = 3–5 per treat-
ment; *, P = 0.015 vs. control), and 14 d (n = 
3–6 per treatment; *, P = 0.02 vs. control; 
#, P < 0.001 vs. denervation) after denervation. 
MuRF1 gene expression was detected by RT-
PCR at 3 d (n = 3–6 per treatment; *, P = 0.04 
vs. control), 7 d (n = 3–5 per treatment; *, P = 
0.03 vs. control; #, P = 0.04 vs. denervation), 
and 14 d (n = 3–6 per treatment; *, P = 0.04 
vs. control; #, P < 0.001 vs. denervation) after 
denervation. Fbxo30/MUSA1 expression was 
detected at 3 d (n = 6 per treatment; *, P < 
0.001 vs. control), 7 d (n = 5–6 per treat-
ment; *, P = 0.01 vs. control; #, P < 0.001 
vs. denervation), and 14 d (n = 4–6 per treat-
ment; *, P = 0.003 vs. control; #, P < 0.05 
vs. denervation) after denervation via RT-PCR. 
(b) Myogenin was measured at 3 d (n = 6 per 
treatment; *, P < 0.001 vs. control), 7 d 
(n = 5–6 per treatment; *, P < 0.05 vs. control; 
#, P = 0.006 vs. denervation), and 14 d (n = 
3–6 per treatment; *, P = 0.003 vs. control; #, 
P < 0.001 vs. denervation) after denervation 
via RT-PCR. (c) HDAC4 protein expression was 
analyzed by Western blotting at 3 d (n = 3–4 
per treatment; *, P = 0.04 vs. control), 7 d 
(n = 6–9 per treatment; *, P < 0.05 vs. control; 
#, P = 0.004 vs. denervation), and 14 d (n = 
4–8 per treatment; *, P = 0.001 vs. control; 
#, P = 0.006 vs. denervation) after denerva-
tion and normalized to GAPDH levels. (d) A 
dominant-negative HDAC4 mutant (HDACD840N) 
was coadministered with rAAV6:Smad6 in 
denervated muscles for 8 d. Western blot-
ting demonstrates that Smad6 protein expres-
sion was not affected by coadministration of 
rAAV6:Smad6 with rAAV6:HDAC4D840N (n = 
5–9 per treatment; *, P < 0.001 vs. control; 
#, P < 0.001 vs. den; +, P = 0.005 vs. Smad6 
in denervation). (e) Representative H&E stained 
images demonstrate that myofiber size is in-
creased when rAAV6:Smad6 is coadminis-
tered with rAAV6:HDAC4D840N, as verified 
by quantification of myofiber diameter. Bar, 
100 µm. Myofiber diameter is presented as box 
and whisker plots comprising minimum, lower 
quartile, median, upper quartile, and maxi-
mum values (n = 3 per treatment; *, P < 0.001 
vs. control; #, P < 0.001 vs. den; +, P < 0.001 
vs. Smad6 in denervation). (f) Myogenin (*, P = 
0.002 vs. control; #, P = 0.02 vs. den; +, 
P = 0.02 vs. Smad6 in denervation) gene ex-
pression was determined using TaqMan gene 
expression assays 8 d after denervation (n = 
5–10 per treatment). (g) E3 ligases including Fbxo30/MUSA1 (*, P < 0.001 vs. control; #, P < 0.001 vs. den; +, P = 0.03 vs. Smad6 in denervation), 
atrogin1 (*, P < 0.001 vs. control; #, P < 0.001 vs. den; +, P = 0.008 vs. Smad6 in denervation), and MuRF1 (*, P < 0.001 vs. control; #, P < 0.001 vs. 
den; +, P = 0.009 vs. Smad6 in denervation) were also measured in muscles collected 8 d after denervation (n = 5–10 per treatment). Data are presented 
as means ± SEM.
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the mechanism by which BMP receptor stimulation promotes 
muscle hypertrophy in innervated muscles. These findings 
contrast with the documented inhibitory effects of the myo-
statin/activin–Smad2/3 axis upon mTOR-mediated signaling 
(Trendelenburg et al., 2009; Winbanks et al., 2012). Our findings 
are consistent with studies of BMP-mediated mTOR activation in 
other cell types (Langenfeld et al., 2005; Townsend et al., 2012). 
Interestingly, increased expression of Smad6 had no effect on 
basal muscle mass and mTOR signaling in the muscles of adult 
mice. These findings suggest that endogenous levels of Smad1/5/8 
phosphorylation do not regulate basal muscle mass, distinct from 
of the effects of the canonical TGF- signaling pathway. Specifi-
cally, Smad2/3 has been shown to actively repress muscle anab-
olism, such that activation or inhibition of Smad2/3 promotes 
atrophy or hypertrophy of skeletal muscle, respectively (Sartori 
et al., 2009; Winbanks et al., 2012). Collectively, the data indicate 
the canonical TGF- signaling pathway uses Smad2/3 as a domi-
nant regulator of basal skeletal muscle mass, whereas the BMP 
signaling pathway is recruited to promote muscle hypertrophy.
We observed that Smad1/5 phosphorylation is altered in 
states of muscle growth. During postnatal maturation of muscles 
in rodents, protein synthesis has been shown to decline markedly 
from 1 wk of age (Suryawan et al., 2006). In support of a role for 
the BMP signaling axis associated with the regulation of neona-
tal muscle development, we demonstrate that Smad1/5 phos-
phorylation markedly declines in correlation with reported 
reductions in protein synthesis. In adult musculature, we demon-
strated that follistatin-mediated muscle hypertrophy (previously 
considered a function of Smad2/3 inhibition via antagonism 
of myostatin and activin) is associated with, and requires, phos-
phorylation of BMP-regulated Smad proteins to achieve maxi-
mal effect. Follistatin may promote Smad1/5/8 phosphorylation 
by binding and presenting endogenous BMP ligands to their 
cognate receptor (Amthor et al., 2002). Alternatively, the se-
questration of myostatin/activin by follistatin could enable en-
dogenous BMP ligands to engage common receptors for which 
myostatin and activin have a higher affinity. This hypothesis is 
consistent with evidence that myostatin can inhibit the phosphory-
lation of Smad1/5 by preventing receptor engagement by BMP 
ligands in adipogenic cells (Rebbapragada et al., 2003).
Our studies suggest the BMP–Smad1/5/8 signaling path-
way is repressed in muscle by mechanisms dependent on motor 
nerve activity, as we observed increased Smad1/5 phosphoryla-
tion in muscles after motor nerve inactivity, degeneration, and 
resection. The models in which we observed elevated Smad1/5 
phosphorylation mimic muscle wasting associated with inten-
sive care unit–related acute myopathy, amyotrophic lateral scle-
rosis, and nerve trauma, respectively, which suggests increased 
BMP signaling is a factor in clinically relevant states of muscle 
wasting. Seeking to determine why Smad1/5 phosphorylation 
was increased in denervated muscle, we found that the expres-
sion of two BMP ligands, GDF5 and GDF6, and the type-IB 
BMP receptor, ALK6, were robustly increased after denerva-
tion. Interestingly, in other tissues, GDF-5 signaling is highly 
dependent on ALK6 expression (Nickel et al., 2005). Other 
BMP ligands such as BMP4 may also potentiate BMP signaling 
at later time points after denervation. We also observed that 
denervated muscles via the administration of rAAV6:Smad6 ro-
bustly increased the transcription of myogenin when compared 
with the effect of denervation alone (Fig. 5 b). Further supporting 
a role for the HDAC4–myogenin axis as a target for repression 
by phosphorylated Smad1/5 in denervated muscles, we observed 
that HDAC4 gene and protein expression were significantly in-
creased when BMP signaling was inhibited by rAAV6:Smad6 
administration after nerve resection (Fig. 5 c and Fig. S5 a). We 
generated an rAAV6 vector designed to express a HDAC4 mu-
tant (HDAC4D840N) in which a single base pair mutation abro-
gates physical interaction with HDAC3, thereby abolishing the 
activity of HDAC4 (Fischle et al., 2002). Administration of 
rAAV6:HDAC4D840N to denervated muscles, which was readily 
detected in denervated skeletal muscle, reduced the ensuing mus-
cle atrophy (Fig. S5, b–d). As HDAC4 is a key regulator of myo-
genin expression in denervated muscles and myogenin plays an 
indispensible role promoting neurogenic atrophy, we determined 
that HDAC4D840N also inhibited the expression of myogenin 
(Fig. S5 e). Significantly, when codelivered with rAAV6:Smad6, 
HDAC4D840N prevented the exacerbation of muscle atrophy by 
rAAV6:Smad6, despite sustained Smad6 protein expression and 
inhibition of Smad1/5 phosphorylation (Fig. 5, d and e). Impor-
tantly, whereas rAAV6:Smad6 up-regulated the expression of 
myogenin in denervated muscles, HDAC4D840N repressed myo-
genin induction and the subsequent transcription of the E3 li-
gases MuRF1, atrogin1, and Musa1/Fbxo30 (Fig. 5, f and g). 
These data demonstrate that in denervated muscles the BMP–
Smad1/5 signaling axis is engaged to preserve muscle mass by 
suppressing the activity of the atrophy-inducing HDAC4–
myogenin–E3 ubiquitin ligase axis.
Discussion
Our findings identify a new, essential role of the BMP–Smad1/5/8 
axis in the regulation of skeletal muscle mass during growth and 
wasting. Increasing signaling via the BMP pathway can promote 
myofiber hypertrophy by stimulating mTOR-dependent anabolic 
mechanisms. Importantly, the BMP–Smad1/5/8 signaling path-
way is vital for conservation of muscle mass after loss of motor 
nerve activity. As augmentation of BMP signaling can protect 
muscles from denervation-induced atrophy, the BMP–Smad1/5/8 
signaling pathway may represent a new target for the develop-
ment of therapeutics to ameliorate muscle wasting.
In mature skeletal muscle, activation of the canonical 
TGF- signaling pathway—chiefly via myostatin- and activin-
promoting phosphorylation of Smad2/3—suppresses protein 
synthesis and promotes protein catabolism. Our data reveal 
BMP–Smad1/5/8 signaling as operating counter to the myostatin/
activin–Smad2/3 axis, as an important promoter of anabolism 
and inhibitor of muscle wasting. The stimulation of muscle hy-
pertrophy via increased expression of BMP7 or a constitu-
tively active type-I BMP receptor uses phosphorylation of 
Smad1/5/8 to activate mTOR-mediated protein synthesis. Inhi-
bition of Smad1/5/8 phosphorylation or mTOR activity pre-
vented BMP-induced muscle hypertrophy and mTOR-mediated 
anabolic signaling (and in the case of direct mTOR inhibition, 
despite continued phosphorylation of Smad1/5), thus confirming 
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limit neurogenic muscle atrophy (Fig. 6). Although HDAC4D840N 
did not completely prevent denervation-induced myogenin and 
E3 ligase induction in the presence of blunted BMP signaling, 
we hypothesize that this may be a result of functional redun-
dancy between class II HDAC proteins (Potthoff et al., 2007; 
Moresi et al., 2010). Although it is unclear how the BMP signal-
ing pathway interacts with HDAC proteins, it has been estab-
lished that BMP-regulated Smad1/5 can repress transcription 
of myogenin (Katagiri et al., 1997; Yamamoto et al., 1997). In 
the case of denervated muscles demonstrating increased BMP–
Smad1/5/8 signaling, it is therefore possible that phosphory-
lated Smad1/5 proteins repress both HDACs and myogenin, 
thereby inhibiting their ability to drive expression of the afore-
mentioned E3 ligases (Fig. 6). As the genetic ablation of the 
HDACs and myogenin renders muscles resistant to denerva-
tion-induced wasting, and the activity of Smad1/5 appears criti-
cal for limiting the induction of HDAC–myogenin signaling, 
our studies suggest there may be considerable potential to ame-
liorate neurogenic muscle atrophy in clinical conditions using 
interventions that enhance the BMP–Smad1/5/8 signaling axis 
in skeletal musculature.
Although our studies have focused on the effect of BMP–
Smad1/5 signaling in skeletal muscle, it is intriguing to note that 
local release of BMP ligands from musculature has been de-
scribed as critical for supporting nerve terminal development and 
establishment of the neuromuscular junction (McCabe et al., 
2003; Ball et al., 2010). Furthermore, some neuromuscular dis-
orders may be associated with perturbed BMP activity (Pescatori 
et al., 2007; Bayat et al., 2011). Accordingly, although our data 
demonstrate that increased expression of specific BMPs in mus-
cle contributes to autocrine BMP-mediated signaling that is vital 
to limit catabolism in denervated muscles, it is possible that in-
creased BMP expression by denervated muscles may also be 
stimulated to promote remodeling and/or regeneration of motor 
transcription of the endogenous inhibitory proteins Noggin and 
Smad6 was repressed in denervated muscles. The coordinated 
regulation of so many elements within the BMP–Smad1/5/8 
axis would account for the increased Smad1/5 phosphorylation 
observed and indicate that engagement of BMP-mediated sig-
naling plays a significant role in the response of skeletal mus-
cles to perturbation/loss of motor nerve activity (Fig. 6).
We sought to define the functional role of increased BMP 
signaling in denervated muscles by inhibiting BMP-mediated 
Smad1/5 phosphorylation, via increased expression of the en-
dogenous inhibitory protein Smad6. Strikingly, we found that 
increased expression of Smad6 in denervated skeletal muscles 
exacerbated neurogenic muscle atrophy. These data suggest that 
BMP signaling is activated in denervated skeletal muscle to 
protect against neurogenic muscle atrophy. In support of these 
findings, potentiation of BMP signaling via administration 
of rAAV6:BMP7 and rAAV6:ALK3 attenuated denervation- 
induced muscle wasting. We determined that the transcription 
of specific E3 ubiquitin ligases previously associated with mus-
cle atrophy (MuRF1, atrogin1, and the more recently identified 
Fbxo30/Musa1) is substantially increased in denervated mus-
cles when BMP–Smad1/5/8 signaling is inhibited (Fig. 6). The 
transcription of MuRF1 and atrogin1 can be promoted by in-
creased activity of the HDAC–myogenin signaling cascade in 
muscle, which itself has been implicated as a key driver of neu-
rogenic muscle atrophy (Moresi et al., 2010). Accordingly, we 
observed that the inhibition of BMP–Smad1/5/8 signaling in 
denervated muscles markedly potentiated the atrophy-inducing 
HDAC–myogenin signaling cascade. Critically, as coadminis-
tering a dominant-negative HDAC4 with rAAV6:Smad6 to de-
nervated muscles significantly prevented muscle wasting and 
the induction of myogenin, MuRF1, atrogin1, and Fbxo30/
Musa1, our data supports a model whereby BMP signaling sup-
presses HDAC4–myogenin signaling in denervated muscles to 
Figure 6. Proposed schema of how the BMP 
signaling axis limits neurogenic muscle wast-
ing. In muscles undergoing neurogenic atro-
phy, the transcription of BMP ligands GDF5 
(BMP14) and GDF6 (BMP13) is increased 
prominently within skeletal muscle, along 
with transcription of the type-IB BMP receptor 
(ALK6) and suppression of the endogenous in-
hibitor Smad6. The net effect is an increase 
in Smad1/5/8 phosphorylation. Expression 
of Smad6 in denervated skeletal muscle exac-
erbates wasting by suppressing Smad1/5/8 
phosphorylation, which in turn potentiates 
the HDAC4–myogenin pathway, leading to 
increased transcription of E3 ubiquitin ligases 
associated with muscle proteolysis, including 
MuRF1, atrogin1, and Fbxo30/MUSA1.
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before denervation. For tissue harvest, mice were humanely killed via cervi-
cal dislocation and the muscles were rapidly excised and weighed before 
subsequent processing. For examination of muscle wasting in a mouse model 
of amyotrophic lateral sclerosis, transgenic SOD1G93A mice derived from the 
B6SJL-TgN (SOD1-G93A) 1Gur line (The Jackson Laboratory) were back-
crossed onto a pure C57BL/6 background. At the designated time points, 
SOD1G93A mice and nontransgenic wild-type littermates were killed by lethal 
injection (100 mg/kg sodium pentobarbitone, intraperitoneally) and the TA 
muscles were rapidly dissected for processing. For examination of muscle 
wasting in a rodent model of intensive care unit myopathy, muscle samples 
were obtained from female Sprague-Dawley rats, representing a subsample 
generated from a previous study (Ochala et al., 2011). The experimental rats 
were anaesthetized, treated with the neuromuscular blocker -cobratoxin, 
and mechanically ventilated for durations varying from 3 to 13 d. The experi-
mental model has previously been described in detail (Dworkin and 
Dworkin, 1990; Dworkin and Dworkin, 2004). In brief, the following sur-
gery and instrumentation was completed with sterile technique: (1) Precordial 
silver wire electrocardiogram electrodes were implanted subcutaneously. 
(2) An aortic catheter (28-gauge Teflon) was inserted via the left carotid ar-
tery to record arterial blood pressure. (3) A 0.9-mm Renathane catheter was 
threaded into the left jugular vein to administer parental solutions. (4) Three 
subcutaneous electroencephalography (EEG) needle electrodes were placed 
into the skull above the right and left temporal lobes, and a third reference 
electrode was placed in the neck region. (5) Temperature was measured by 
a vaginal thermistor and servo-regulated at 37°C. (6) A silicone cannula was 
inserted in the urethra to continuously record urine output. The sham-operated 
control animals underwent the same interventions as the controls, but they 
were not pharmacologically paralyzed with -cobratoxin. That is, sham-oper-
ated controls were anesthetized (isoflurane), spontaneously breathing, given 
intraarterial and i.v. solutions, and killed within 2 h after the initial anesthesia 
and surgery. During surgery or any possible irritating manipulation, the an-
esthetic isoflurane level was >1.5%, which maintained the following states: 
(a) the EEG was synchronized and dominated by high-voltage slow-wave 
activity; (b) mean arterial pressure was 100 mmHg and the heart rate 
420 beats/min; and (c) there were no evident EEG, blood pressure, or heart 
rate responses to surgical manipulation. Isoflurane was delivered into the in-
spiratory gas stream by a precision mass-flow controller. After the ini-
tial surgery, isoflurane was gradually lowered (over 1 to 2 d) and maintained 
at <0.5% during the remaining experimental period. Rats were ventilated 
through a per os coaxial tracheal cannula at 72 breaths/min with an inspira-
tory and expiratory ratio of 1:2 and a minute volume of 180–200 ml and 
gas concentrations of 50% O2, 47% N2, and 3% CO2, delivered by a precision 
volumetric respirator. Intermittent respiratory hyperinflations (6 per hour at 
15 cmH2O), positive end-expiratory pressure (1.5 cmH2O), and expiratory 
CO2 monitoring were continuous. Neuromuscular blockade was induced on 
the first day (100 µg -cobratoxin, i.v.) and maintained by continuous infusion 
(250 µg/d, i.v.). Mechanical ventilation was initiated immediately after the 
neuromuscular blockade induction. In no case did animals show any signs 
of infections or septicemia. The ethics committee at Uppsala University ap-
proved all aspects of the rodent intensive care unit myopathy study.
Real-time PCR
Total RNA was collected from TA muscles cells using Trizol (Invitrogen). 
500–1,000 ng of RNA was reverse transcribed using the High Capacity 
RNA-to-cDNA kit (Applied Biosystems). Expression levels of all genes ana-
lyzed were determined via RT-PCR using Taqman assay on demand kits 
(Applied Biosystems) and detection software (Applied Biosystems). For de-
tection of BMP7 gene expression, Sybr Green analysis was used (forward: 
5-ggctggcaggactggatcat-3; reverse: 5-ggcgcacagcagggcttgg-3). In all 
cases, 18S was used to standardize cDNA concentrations. Data were ana-
lyzed using the CT method of analysis and the control cohort is normal-
ized to a value of 1.
Luciferase experiments
C2C12 cells were either transfected in 24-well plates with 0.35 µg 
Smad6, ALK3, or BMP7 plasmid and 0.25 µg BRE-Luc plasmid or 0.25 µg 
-galactosidase expression plasmid per well using lipofectamine 2000 (Invi-
trogen). Where appropriate, media was changed 16 h later and supple-
mented with either vehicle or 3 nM BMP4 for 24 h. Cells were then lysed 
with cell lysis buffer (Promega) and luciferase activity was measured using a 
Berthold Luminometer. Luciferase activity is presented as the ratio of BRE-
luciferase activity to -galactosidase reporter activity. -Galactosidase was 
detected using a -galactosidase detection assay (Promega). In brief, lysate 
was incubated with 2× -galactosidase buffer for 30 min to 1 h at 37°C and 
expression was then measured at 420 nm.
nerve terminals and the neuromuscular junction. Our ongoing 
research seeks to determine the significance of muscle-derived 
BMP ligands in developing and maintaining the integral relation-
ship between the motor nerve and muscle fibers in the context of 
neuromuscular disorders and neurogenic muscle wasting.
In conclusion, we demonstrate for the first time that the 
BMP signaling axis is a bona fide positive regulator of skeletal 
muscle mass. This role of BMP–Smad1/5/8 signaling sits in 
marked contrast to the established negative role of the canonical 
TGF- signaling cascade in muscle, which is chiefly considered 
as the myostatin/activin–Smad2/3 signaling axis. Our studies in-
dicate BMP–Smad1/5/8 signaling is potentiated upon perturba-
tion/loss of motor nerve activity to conserve muscle mass. As 
our data demonstrate that enhancing BMP signaling is protective 
in models of neurogenic atrophy, we propose that interventions 
targeting the BMP–Smad1/5 axis may hold exciting potential as 
therapeutics capable of ameliorating muscle wasting and should 
be investigated accordingly.
Materials and methods
Antibodies
All antibodies used were obtained from Cell Signaling Technology, except 
for antibodies against pSmad3 (Epitomics) and GAPDH (Santa Cruz Bio-
technology, Inc.).
Production of rAAV6 vectors
cDNA constructs encoding follistatin-288, Smad6, BMP7, constitutively ac-
tive ALK3 (GenScript), and HDACD840N (Fischle et al., 2002) were cloned 
into an rAAV2 expression plasmid consisting of a CMV promoter/enhancer 
(with the exception of HDAC4D840N containing a muscle-specific CK6 pro-
moter) and SV40 poly-A region flanked by rAAV2 terminal repeats using 
standard cloning techniques. Transfection of these plasmids with the pDGM6 
packaging plasmid into HEK293 cells generated type-6 pseudotyped viral 
vectors that were harvested and purified as described previously (Gregorevic 
et al., 2004). In brief, HEK293 cells were plated at a density of 3.23.8 × 
106 cells on 10-cm culture dishes, 816 h before transfection with 10 µg of 
a vector-genome–containing plasmid and 20 µg of the packaging/helper 
plasmid pDGM6, by means of the calcium phosphate precipitate method to 
generate pseudotype 6 vectors. 72 h after transfection, the media and cells 
were collected and homogenized through a microfluidizer (Microfluidics) 
before 0.22-µm clarification (EMD Millipore). The vector was purified from 
the clarified lysate by affinity chromatography over a HiTrap heparin col-
umn (GE Healthcare) and ultracentrifuged overnight before resuspension in 
sterile physiological Ringer’s solution. The purified vector preparations were 
titered with a customized sequence-specific quantitative PCR-based reaction 
(Applied Biosystems).
Animal experiments
All experiments were conducted in accordance with the relevant codes of 
practice for the care and use of animals for scientific purposes (National In-
stitutes of Health and National Health and Medical Council of Australia). For 
local vector delivery, mice were deeply anesthetized with isoflurane, and 
109–2.5 × 1010 vector genomes of a given vector were injected in 30 µl of 
HBSS directly into the anterior compartment of the hindlimb, which is occu-
pied by the TA and extensor digitorum longus muscles. Control injections of 
the contralateral limb used a vector lacking a functional gene (referred to as 
rAAV6:MCS). For rapamycin experiments, rapamycin was dissolved over-
night in a solution containing 0.2% carboxymethylcellulose sodium salt 
(Sigma-Aldrich) and 0.25% polysorbate-80 (Sigma-Aldrich) in water, as de-
scribed previously (Shioi et al., 2003). In these experiments, 8-wk-old mice 
received 1 mg/kg/day of rapamycin (EMD Millipore) or vehicle as a daily 
intraperitoneal injection commencing 3 h before rAAV6:BMP7 injection and 
continuing for 28 d inclusive. For experiments examining denervation- 
induced muscle atrophy, 6–8-wk-old mice were deeply anaesthetized and an 
incision was made laterally below the knee. Here, a 1-mm portion of the pe-
roneal nerve was removed to denervate the TA muscle. While the mouse was 
under anesthesia, the anterior hindlimb was injected with the appropriate 
vector, except for rAAV6:BMP7 and rAAV6:ALK3, which were injected 4 wk 
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Histology
Harvested muscles were placed in Optimal Cutting Temperature cryoprotec-
tant (Sakura) and frozen in liquid nitrogen–cooled isopentane. The frozen 
samples were subsequently cryosectioned at 10-µm thickness and stained 
with hematoxylin and eosin (H&E) to examine morphology as described pre-
viously (Rafael et al., 1996). Sections were mounted using DePeX mounting 
medium (BDH) and images of stained sections were captured at room tem-
perature using a U-TV1X-2 camera mounted to an IX71 microscope (Olym-
pus) and a PlanC 10×/0.25 objective lens (Olympus). DP2-BSW acquisition 
software (Olympus) was used to acquire images. Myofiber size and area 
was determined by placing TA muscles in Optimal Cutting Temperature and 
freezing in liquid nitrogen–cooled isopentane. The sarcolemma of muscle fi-
bers was then identified using an antibody raised against laminin. In brief, 
10-µm sections were fixed in methanol, and then washed in PBS containing 
0.2% Tween-20 and subsequently blocked in 5% normal goat serum. Sec-
tions were then incubated with rat anti-laminin antibody (EMD Millipore) and 
a secondary goat anti–rat antibody Alexa 594 (Molecular Probes) was used 
as the fluorescent label, followed by mounting in Vectashield HardSet (Vec-
tor Laboratories). Fluorescent images were taken on a microscope (BX61; 
Olympus). The minimum Feret’s diameter and myofiber area were deter-
mined using ImageJ software by measuring at least 600 myofibers per 
mouse TA muscle and at least three mice were used per group to quantify 
these variables.
Western blotting
TA muscles were homogenized in RIPA-based lysis buffer (EMD Millipore) 
with Complete EDTA-free protease and phosphatase inhibitor cocktails 
(Roche). Lysis was followed by centrifugation at 13,000 g for 10 min at 4°C 
and samples were denatured for 5 min at 95°C. Protein concentration was 
determined using a Pierce protein assay kit (Thermo Fisher Scientific). Protein 
fractions were subsequently separated by SDS-PAGE using precast 4–12% 
Bis-Tris gels (Invitrogen), blotted onto nitrocellulose membranes (Bio-Rad Lab-
oratories), and incubated with the appropriate antibody overnight and de-
tected as described previously (Winbanks et al., 2011). Quantification of 
labeled Western blots was performed using ImageJ pixel analysis (National 
Institutes of Health Image software), and data are normalized to a control 
value of 1. Densitometric analyses of Western blots are presented as band 
density normalized to the loading control. In cases of phosphorylated pro-
teins, the loading control is the total protein level of that phosphorylated pro-
tein. Total protein levels have been quantified by using GAPDH as the 
loading control.
Statistical analysis
One- or two-way analyses of variance were used to assess statistical differ-
ences across multiple conditions, with the Student-Newman-Keuls post-hoc 
test used for comparisons between the specific group means. Comparisons 
between two conditions only used the Students’ t test. Statistics on myofiber 
diameter were performed on all raw data within a treatment, not on quartile 
values. Data are reported as statistically significant when P < 0.05 for com-
parisons. Data are presented as the mean ± SEM.
Online supplemental material
Fig. S1 shows that rAAV6:ALK3 can regulate IGF transcription and pro-
vides supportive evidence of the ability of rAAV6:BMP7-induced growth to 
be regulated by mTOR signaling. Fig. S2 demonstrates that Smad6 does 
not alter basal skeletal muscle mass. Fig. S3 demonstrates the dependency 
of follistatin-induced muscle growth on BMP signaling in vivo. Fig. S4 illus-
trates a transcriptional profile of BMP ligands and BMP inhibitors in dener-
vated muscles and also demonstrates that rAAV6:Smad6 does not regulate 
Foxo and Akt signaling in denervation. Fig. S5 confirms that the adminis-
tration of rAAV6:HDAC4D840N is protective in denervation-induced muscle 
wasting. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201211134/DC1.
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Figure S1.  Rapamycin prevents hypertrophy induced by rAAV6:BMP7. (a) IGF1 and IGF2 transcription was measured in TA muscles examined 28 d after 
administration of rAAV6:ALK3 (*, P = 0.005 vs. control; n = 4 per treatment). (b) FoxO1T24/FoxO3aT32 phosphorylation and total abundance was mea-
sured 28 d after rAAV6:BMP7 administration by Western blotting (P = ND). (c) Transcription of the E3 ubiquitin ligases atrogin1, MuRF1, and Musa1/
Fbxo30 was measured by RT-PCR in muscle examined 28 d after administration of rAAV6:BMP7. P = ND. (d) Representative H&E images demonstrate ra-
pamycin prevents hypertrophy of myofibers otherwise caused by administration of rAAV6:BMP7. Bar, 100 µm. (e and f) BMP7 mRNA (n = 7–8 per treat-
ment) and protein expression (n = 3 per treatment) were measured 28 d after rAAV6:BMP7 administration in the presence of rapamycin or vehicle. RT-PCR 
data are presented according to the CT method of analysis and normalized to a value of 1 (*, P = 0.008 vs. control; #, P = 0.02 vs. control). (g) The ad-
ministration of rapamycin to mice did not prevent the phosphorylation of Smad1/5 in muscles administered rAAV6:BMP7 (n = 4 per treatment; *, P = 0.03 
vs. control; #, P = 0.01 vs. control). Data are presented as means ± SEM.
JCB S2 
Figure S2.  Increased expression of Smad6 does not alter basal skeletal muscle mass. (a) Administration of rAAV6:Smad6 to mouse muscles 28 d before 
examination potently suppressed Smad1/5S463/465 phosphorylation, as determined by Western blot (n = 3 per treatment; *, P = 0.005 vs. control). (b) TA 
muscle mass as recorded 28 d after administration of rAAV6:Smad6. n = 3 per treatment. ND, not different. (c) The administration of rAAV6:Smad6 to 
mouse limb muscles did not alter the phosphorylation of AktS473, mTORS2448, S6RPS235/236, or 4EBP1T37/46 as determined by Western blot (ND, not different). 
n = 3–7 per treatment. Data are presented as means ± SEM.
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Figure S3.  Hypertrophy of skeletal muscle alters the phosphorylation of BMP-regulated Smads. (a) Smad1/5S463/465 phosphorylation was assessed in 
mouse TA muscles injected 28 d earlier with rAAV6:Fst-288 (n = 7–8 per treatment; *, P < 0.001 vs. control). (b) Smad6 transcription was measured by RT-
PCR in TA muscles examined 28 d after administration of rAAV6:Fst (n = 5 per treatment; *, P = 0.005 vs. control). (c) TA muscles were administered rAAV6:
Fst-288 alone or rAAV6:Fst-288 and rAAV6:Smad6 28 d before analysis (n = 4–7 per treatment; *, P < 0.001 vs. control; #, P < 0.001 vs. Fst-288 treated 
muscles). (d) Representative images demonstrate the repressive effect of Smad6 on follistatin-288–induced TA muscle hypertrophy. Bar, 5 mm. (e) Represen-
tative H&E images and quantification demonstrate that Smad6 attenuates follistatin-mediated increases in myofiber diameter (*, P < 0.001 vs. control; *, 
P < 0.001 vs. Fst-288) and area (*, P < 0.001 vs. control; *, P < 0.001 vs. Fst-288). Myofiber diameter is presented as box and whisker plots comprising 
minimum, lower quartile, median, upper quartile, and maximum values for myofiber diameter. Bar, 100 µm. (f) Protein expression of follistatin and Smad6 
as determined by Western blot. rAAV6:Smad6 reduced Smad1/5S463/465 phosphorylation (n = 8–14 per treatment; *, P = 0.045 vs. control; #, P < 0.001 
vs. control; +, P = 0.004 vs. Fst-288). (g) The phosphorylation of AktS473 (*, P = 0.03 vs. control; #, P = 0.009 vs. Fst-288), mTORS2448 (*, P = 0.03 vs. con-
trol; #, P = 0.02 vs. Fst-288), S6RPS235/236 (*, P = 0.002 vs. control; #, P = 0.004 vs. Fst-288), and 4EBP1T37/46 (*, P = 0.02 vs. control; #, P = 0.009 vs. 
Fst-288) was assessed in response to the administration of rAAV6:Smad6 and rAAV6:Fst-288 by Western blot. n = 4–9 per treatment. Data are presented 
as means ± SEM.
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Figure S4.  Transcription of BMP ligands and BMP pathway inhibitors in denervated muscles. (a) Expression of BMP ligands 1–7 and BMP 15 was deter-
mined by RT-PCR at 3 d (n = 6 per treatment), 7 d (n = 5–6 per treatment), and 14 d (n = 3–6 per treatment) after denervation in TA muscles. (b) Expression 
of BMP negative regulators Smad7, Smurf1, Smurf2, and Chordin was determined at 3 d (n = 6 per treatment), 7 d (n = 5–6 per treatment), and 14 d (n 
= 3–6 per treatment) after denervation by RT-PCR. Data are presented as means ± SEM. (c) TA muscles were homogenized 14 d after denervation and ad-
ministration of rAAV6:Smad6 or sham vector. Lysates were analyzed by Western blotting for AktS473 (n = 4–5 per treatment; *, P < 0.001 vs. control) and 
FoxO1T24/FoxO3aT32 phosphorylation (n = 6–8 per treatment; *, P = 0.03 vs. control). Data are presented as means ± SEM.
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Figure S5.  Effect of dominant-negative HDAC4 in denervation-induced muscle wasting. (a) HDAC4 transcription was measured at 3 d (*, P < 0.001 vs. 
control; n = 6 per treatment), 7 d (n = 5–6 per treatment; *, P = 0.015 vs. control; #, P < 0.001 vs. denervation), and 14 d (n = 3–6 per treatment; *, P 
= 0.02 vs. control; #, P < 0.001 vs. denervation) after denervation via RT-PCR. (b–d) TA muscles were denervated and treated with rAAV6:HDAC4D840N 8 
d before analysis, at which time, muscle mass (*, P < 0.001 vs. control; #, P = 0.02 vs. denervation) and myofiber diameter (*, P < 0.001 vs. control; #, 
P = 0.004 vs. denervation) was assessed. n = 4–5 per treatment. Expression of the dominant-negative HDAC4 mutant in denervated muscle was readily 
detectable by Western blot. Myofiber diameter is presented as box and whisker plots comprising minimum, lower quartile, median, upper quartile, and 
maximum values. Bar, 100 µm. (e) Myogenin transcription was measured by RT-PCR in muscles examined 8 d after denervation while transduced with 
rAAV6:HDAC4D840N or sham vector (*, P < 0.001 vs. control; #, P = 0.007 vs. den; n = 3–5 per treatment).
